Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tobin, Richard P. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: International immunopharmacology - Laupland, Kevin B. ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:63 ; year:2018 ; pages:282-291 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.intimp.2018.08.007 |
|---|
| Katalog-ID: |
ELV043949363 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV043949363 | ||
| 003 | DE-627 | ||
| 005 | 20230624105611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181113s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2018.08.007 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica |
| 035 | |a (DE-627)ELV043949363 | ||
| 035 | |a (ELSEVIER)S1567-5769(18)30384-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Tobin, Richard P. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| 264 | 1 | |c 2018 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. | ||
| 700 | 1 | |a Jordan, Kimberly R. |4 oth | |
| 700 | 1 | |a Robinson, William A. |4 oth | |
| 700 | 1 | |a Davis, Dana |4 oth | |
| 700 | 1 | |a Borges, Virginia F. |4 oth | |
| 700 | 1 | |a Gonzalez, Rene |4 oth | |
| 700 | 1 | |a Lewis, Karl D. |4 oth | |
| 700 | 1 | |a McCarter, Martin D. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Laupland, Kevin B. ELSEVIER |t International immunopharmacology |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV00785823X |
| 773 | 1 | 8 | |g volume:63 |g year:2018 |g pages:282-291 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.intimp.2018.08.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.75 |j Infektionskrankheiten |j parasitäre Krankheiten |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 63 |j 2018 |h 282-291 |g 10 | ||
| author_variant |
r p t rp rpt |
|---|---|
| matchkey_str |
tobinrichardpjordankimberlyrrobinsonwill:2018----:agtnmeodeiesprsoclssnalrnrtniaiimlnmp |
| hierarchy_sort_str |
2018 |
| bklnumber |
44.75 |
| publishDate |
2018 |
| allfields |
10.1016/j.intimp.2018.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica (DE-627)ELV043949363 (ELSEVIER)S1567-5769(18)30384-9 DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Tobin, Richard P. verfasserin aut Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab 2018 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. Jordan, Kimberly R. oth Robinson, William A. oth Davis, Dana oth Borges, Virginia F. oth Gonzalez, Rene oth Lewis, Karl D. oth McCarter, Martin D. oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:63 year:2018 pages:282-291 extent:10 https://doi.org/10.1016/j.intimp.2018.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 63 2018 282-291 10 |
| spelling |
10.1016/j.intimp.2018.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica (DE-627)ELV043949363 (ELSEVIER)S1567-5769(18)30384-9 DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Tobin, Richard P. verfasserin aut Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab 2018 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. Jordan, Kimberly R. oth Robinson, William A. oth Davis, Dana oth Borges, Virginia F. oth Gonzalez, Rene oth Lewis, Karl D. oth McCarter, Martin D. oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:63 year:2018 pages:282-291 extent:10 https://doi.org/10.1016/j.intimp.2018.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 63 2018 282-291 10 |
| allfields_unstemmed |
10.1016/j.intimp.2018.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica (DE-627)ELV043949363 (ELSEVIER)S1567-5769(18)30384-9 DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Tobin, Richard P. verfasserin aut Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab 2018 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. Jordan, Kimberly R. oth Robinson, William A. oth Davis, Dana oth Borges, Virginia F. oth Gonzalez, Rene oth Lewis, Karl D. oth McCarter, Martin D. oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:63 year:2018 pages:282-291 extent:10 https://doi.org/10.1016/j.intimp.2018.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 63 2018 282-291 10 |
| allfieldsGer |
10.1016/j.intimp.2018.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica (DE-627)ELV043949363 (ELSEVIER)S1567-5769(18)30384-9 DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Tobin, Richard P. verfasserin aut Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab 2018 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. Jordan, Kimberly R. oth Robinson, William A. oth Davis, Dana oth Borges, Virginia F. oth Gonzalez, Rene oth Lewis, Karl D. oth McCarter, Martin D. oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:63 year:2018 pages:282-291 extent:10 https://doi.org/10.1016/j.intimp.2018.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 63 2018 282-291 10 |
| allfieldsSound |
10.1016/j.intimp.2018.08.007 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica (DE-627)ELV043949363 (ELSEVIER)S1567-5769(18)30384-9 DE-627 ger DE-627 rakwb eng 610 VZ 44.75 bkl Tobin, Richard P. verfasserin aut Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab 2018 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. Jordan, Kimberly R. oth Robinson, William A. oth Davis, Dana oth Borges, Virginia F. oth Gonzalez, Rene oth Lewis, Karl D. oth McCarter, Martin D. oth Enthalten in Elsevier Science Laupland, Kevin B. ELSEVIER International immunopharmacology 2022 Amsterdam [u.a.] (DE-627)ELV00785823X volume:63 year:2018 pages:282-291 extent:10 https://doi.org/10.1016/j.intimp.2018.08.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 63 2018 282-291 10 |
| language |
English |
| source |
Enthalten in International immunopharmacology Amsterdam [u.a.] volume:63 year:2018 pages:282-291 extent:10 |
| sourceStr |
Enthalten in International immunopharmacology Amsterdam [u.a.] volume:63 year:2018 pages:282-291 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Infektionskrankheiten parasitäre Krankheiten |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
International immunopharmacology |
| authorswithroles_txt_mv |
Tobin, Richard P. @@aut@@ Jordan, Kimberly R. @@oth@@ Robinson, William A. @@oth@@ Davis, Dana @@oth@@ Borges, Virginia F. @@oth@@ Gonzalez, Rene @@oth@@ Lewis, Karl D. @@oth@@ McCarter, Martin D. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00785823X |
| dewey-sort |
3610 |
| id |
ELV043949363 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043949363</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624105611.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181113s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.intimp.2018.08.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043949363</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1567-5769(18)30384-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tobin, Richard P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jordan, Kimberly R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robinson, William A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Davis, Dana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borges, Virginia F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gonzalez, Rene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lewis, Karl D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCarter, Martin D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Laupland, Kevin B. ELSEVIER</subfield><subfield code="t">International immunopharmacology</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00785823X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:282-291</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.intimp.2018.08.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2018</subfield><subfield code="h">282-291</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Tobin, Richard P. |
| spellingShingle |
Tobin, Richard P. ddc 610 bkl 44.75 Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| authorStr |
Tobin, Richard P. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00785823X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.75 bkl Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| topic |
ddc 610 bkl 44.75 |
| topic_unstemmed |
ddc 610 bkl 44.75 |
| topic_browse |
ddc 610 bkl 44.75 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k r j kr krj w a r wa war d d dd v f b vf vfb r g rg k d l kd kdl m d m md mdm |
| hierarchy_parent_title |
International immunopharmacology |
| hierarchy_parent_id |
ELV00785823X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
International immunopharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00785823X |
| title |
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| ctrlnum |
(DE-627)ELV043949363 (ELSEVIER)S1567-5769(18)30384-9 |
| title_full |
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| author_sort |
Tobin, Richard P. |
| journal |
International immunopharmacology |
| journalStr |
International immunopharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
282 |
| author_browse |
Tobin, Richard P. |
| container_volume |
63 |
| physical |
10 |
| class |
610 VZ 44.75 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tobin, Richard P. |
| doi_str_mv |
10.1016/j.intimp.2018.08.007 |
| dewey-full |
610 |
| title_sort |
targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with ipilimumab |
| title_auth |
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| abstract |
Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. |
| abstractGer |
Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. |
| abstract_unstemmed |
Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab |
| url |
https://doi.org/10.1016/j.intimp.2018.08.007 |
| remote_bool |
true |
| author2 |
Jordan, Kimberly R. Robinson, William A. Davis, Dana Borges, Virginia F. Gonzalez, Rene Lewis, Karl D. McCarter, Martin D. |
| author2Str |
Jordan, Kimberly R. Robinson, William A. Davis, Dana Borges, Virginia F. Gonzalez, Rene Lewis, Karl D. McCarter, Martin D. |
| ppnlink |
ELV00785823X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.intimp.2018.08.007 |
| up_date |
2024-07-06T20:11:08.427Z |
| _version_ |
1803861799392509952 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV043949363</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624105611.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181113s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.intimp.2018.08.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001217.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV043949363</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1567-5769(18)30384-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tobin, Richard P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint inhibitors have improved overall survival rates for many cancers, yet the majority of patients do not respond to treatment and succumb to disease progression. One tumor-related mechanism limiting the efficacy of immunotherapies in melanoma is the recruitment and expansion of myeloid-derived suppressor cells (MDSCs). Therefore, targeting MDSCs in combination with immunotherapies is an attractive strategy to improve response rates and effectiveness.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jordan, Kimberly R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robinson, William A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Davis, Dana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borges, Virginia F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gonzalez, Rene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lewis, Karl D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCarter, Martin D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Laupland, Kevin B. ELSEVIER</subfield><subfield code="t">International immunopharmacology</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00785823X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:282-291</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.intimp.2018.08.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2018</subfield><subfield code="h">282-291</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.3998823 |